Angiogenic cytokines in mesothelioma: A study of VEGF, FGF-1 and -2, and TGFβ expression

Journal of Pathology

Volumn 189, Issue 1, 1999, Pages 72-78

  Kumar Singh, Samir ^a   Weyler, Joost ^a   Martin, Manuella J H ^a   Vermeulen, Peter B ^a   Van Marck, Eric ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Angiogenesis; Cytokines; FGF 1; FGF 2; IMD; Mesothelioma; Prognosis; TGF ; VEGF

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DENSITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; PRIORITY JOURNAL; TUMOR GROWTH;

CYTOKINES; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GROWTH SUBSTANCES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MALE; MESOTHELIOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032818742     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0     Document Type: Article

References (30)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10 931-10 934.
2. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993; 10: 302-313.
3. Folkman J. Addressing tumor blood vessels. Nature Biotechnol 1997; 15: 510-510.
4. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996; 2: 689-692.
5. Kumar-Singh S, Vermeulen PB, Weyler J, et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997; 182: 211-216.
6. Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 1992; 51: 296-301.
7. Monti G, Jaurand MC, Monnet I, et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment. Cancer Res 1994; 54: 4419-4423.
8. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Patho-and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol Immunother 1994; 39: 347-359.
9. Maeda J, Ueki N, Ohkawa T, et al. Transforming growth factor-beta 1 (TGF-beta 1)-and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer. Clin Exp Immunol 1994; 98: 319-322.
10. Antony VB, Hott JW, Godbey SW, Holm K. Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8. Chest 1996; 109: 21S-22S.
11. Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor beta 2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997; 57: 3200-3207.
12. Tzanakakis GN, Hjerpe A, Karamanos NK. Proteoglycan synthesis induced by transforming and basic fibroblast growth factors in human malignant mesothelioma is mediated through specific receptors and the tyrosine kinase inlracellular pathway. Biochimie 1997; 79: 323-332.
13. Jagirdar J, Lee TC, Reibman J, et al. Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases. Environ Health Perspect 1997; 105 (Suppl 5), 1197-1203.
14. Mutsaers SE, McAnulty RJ, Laurent GJ, Versnel MA, Whitaker D, Papadimitriou JM. Cytokine regulation of mesothelial cell proliferation in vitro and in vivo. Eur J Cell Biol 1997; 72: 24-29.
15. Kumar-Singh S, Van Marck E. Differentiation and differentiating patterns in mesothelioma. In: Peters GA, Peters B, eds. Sourcebook on Asbestos Diseases. Volume 16: Pathogenesis, Diagnosis, Treatment, and Compensation in Mesothelioma. Charlottesville, VA, U.S.A.: Lexus, Publishing: Elsevier, 1998; 213-284.
16. Berse B, Brown LF, Van-de WL, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-220.
17. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
18. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 1996; 2: 1096-1103.
19. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59: 115-165.
20. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22: 339-347.
21. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers [see comments]. J Natl Cancer Inst 1994; 86: 356-361.
22. Ueki T, Koji T, Tamiya S, Nakane PK, Tsuneyoshi M. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. J Pathol 1995; 177: 353-361.
23. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
24. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963-969.
25. Vermeulen PB, Roland L, Mertens V, et al. Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Microvasc Res 1996; 51: 164-174.
26. Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 1997; 181: 67-74.
27. Vermeulen PB, Dirix LY, Martin M, Van Oosterom AT. Serum levels of b-FGF and VEGF in patients with metastatic solid tumours. Proc ASCO 1996; S15: 90 (abstract 25).
28. Imamura T, Engleka K, Zhan X, et al. Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science 1990; 249: 1567-1570.
29. Kumar-Singh S, Jacobs W, Dhaene K, et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentation, WT1 expression and clinical outcome. J Pathol 1998; 186: 300-305.
30. Mali M, Elenius K, Miettinen HM, Jalkanen M. Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1. J Biol Chem 1993; 268: 24 215-24 222.